Grade II Oligodendroglioma

Hemangloblastoma featured new
Hemangioblastoma
October 27, 2021
Cervical Laminectomy feature
Cervical Laminectomy and Fusion
October 27, 2021

Genetic analysis of the tumor, ordered by NSPC neuro-oncologist, Jai Grewal, M.D., revealed mutations and chromosomal translocations suggesting responsiveness to particular chemotherapy regimens.

Treatment with chemotherapy and radiation under the care of Dr. Grewal resulted in a durable response of the tumor as evident in the post-treatment images.

Neurocognitive assessment by NSPC neuropsychologist Gad Klein, Ph.D., was incorporated into the patient’s care. One month following the initiation of chemotherapy, the patient experienced a marked improvement in seizure frequency, and two months later, he became completely seizure-free. He has now been tapered off seizure medications.

The patient has returned to work with a resolution of cognitive impairment, has no neurological impairment, and the tumor continues to shrink on each serial MRI.

Grade II Oligodendroglioma 1

July 2019

Grade II Oligodendroglioma 2

December 2019

CATEGORY: BRAIN // GRADE II OLIGODENDROGLIOMA

Grade II Oligodendroglioma

A 43-year-old man had symptoms of cognitive impairment and frequent jerking involving his right arm.

A brain MRI showed an increased T2 signal in the left frontoparietal area. His tumor was non-enhancing. He underwent a partial resection of the tumor performed by NSPC neurosurgeon Ramin Rak, M.D., with intraoperative monitoring revealing eloquent motor cortex involvement anteriorly. The pathological diagnosis was WHO grade 2 oligodendroglioma.

AUTHORS:
To learn more about the author, click his name or photo:
Share

Authors

To learn more about the author, click his name or photo: